Allogeneic bone marrow transplantation in patients with multiple myeloma

G. Gahrton, S. Tura, C. Belanger, M. Cavo, B. Chapvis, A. Ferrant, M. Flesch, M. Gore, A. Gratwohl, P. J. Graven, J. L. Harrouseau, A. Lindeberg, P. Ljungman, B. Lowenberg, G. Lucarelli, M. Michall et, J. Reiffers, O. Ringden, M. T. Van Lint

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

50 patients with a median age of 41 years (range 29-54) underwent allogeneic bone marrow transplantation for multiple myeloma. 35 patients were on second-line treatment, and 15 on first-line treatment. 24 patients were considered refractory to previous treament. 45 patients received marrow from HLA-matched sibling donors (3 of these from twin donors), and 5 from unrelated or related non-sibling donors. 21 patients entered complete remission, while 15 had persistent disease following repopulation of the marrow. 14 patients were not evaluable for remission status because of early transplantation-related death. The overall median survival from bone marrow transplantation was 27 months, with a projected long-term survival of 34 %. Patients who were 40 yr of age or older had a survival that was not different from that of patients between 29 and 40 yr of age. The median disease-free survival of patients who entered complete remissions was 41 months. These patients tended to have a longer survival than patients with persistent disease following repopulation of the marrow. Allogeneic bone marrow transplantation appears bo be a promising method for treatment of certain patients with multiple myeloma.

Original languageEnglish
Pages (from-to)182-185
Number of pages4
JournalEuropean Journal of Haematology, Supplement
Volume43
Issue number51
Publication statusPublished - 1989

Fingerprint

Homologous Transplantation
Multiple Myeloma
Bone Marrow Transplantation
Survival
Bone Marrow
Tissue Donors
Unrelated Donors
Disease-Free Survival
Siblings
Therapeutics
Transplantation

ASJC Scopus subject areas

  • Hematology

Cite this

Gahrton, G., Tura, S., Belanger, C., Cavo, M., Chapvis, B., Ferrant, A., ... Van Lint, M. T. (1989). Allogeneic bone marrow transplantation in patients with multiple myeloma. European Journal of Haematology, Supplement, 43(51), 182-185.

Allogeneic bone marrow transplantation in patients with multiple myeloma. / Gahrton, G.; Tura, S.; Belanger, C.; Cavo, M.; Chapvis, B.; Ferrant, A.; Flesch, M.; Gore, M.; Gratwohl, A.; Graven, P. J.; Harrouseau, J. L.; Lindeberg, A.; Ljungman, P.; Lowenberg, B.; Lucarelli, G.; Michall et, M.; Reiffers, J.; Ringden, O.; Van Lint, M. T.

In: European Journal of Haematology, Supplement, Vol. 43, No. 51, 1989, p. 182-185.

Research output: Contribution to journalArticle

Gahrton, G, Tura, S, Belanger, C, Cavo, M, Chapvis, B, Ferrant, A, Flesch, M, Gore, M, Gratwohl, A, Graven, PJ, Harrouseau, JL, Lindeberg, A, Ljungman, P, Lowenberg, B, Lucarelli, G, Michall et, M, Reiffers, J, Ringden, O & Van Lint, MT 1989, 'Allogeneic bone marrow transplantation in patients with multiple myeloma', European Journal of Haematology, Supplement, vol. 43, no. 51, pp. 182-185.
Gahrton G, Tura S, Belanger C, Cavo M, Chapvis B, Ferrant A et al. Allogeneic bone marrow transplantation in patients with multiple myeloma. European Journal of Haematology, Supplement. 1989;43(51):182-185.
Gahrton, G. ; Tura, S. ; Belanger, C. ; Cavo, M. ; Chapvis, B. ; Ferrant, A. ; Flesch, M. ; Gore, M. ; Gratwohl, A. ; Graven, P. J. ; Harrouseau, J. L. ; Lindeberg, A. ; Ljungman, P. ; Lowenberg, B. ; Lucarelli, G. ; Michall et, M. ; Reiffers, J. ; Ringden, O. ; Van Lint, M. T. / Allogeneic bone marrow transplantation in patients with multiple myeloma. In: European Journal of Haematology, Supplement. 1989 ; Vol. 43, No. 51. pp. 182-185.
@article{1ce9f34609984da4ab8b12987411efd5,
title = "Allogeneic bone marrow transplantation in patients with multiple myeloma",
abstract = "50 patients with a median age of 41 years (range 29-54) underwent allogeneic bone marrow transplantation for multiple myeloma. 35 patients were on second-line treatment, and 15 on first-line treatment. 24 patients were considered refractory to previous treament. 45 patients received marrow from HLA-matched sibling donors (3 of these from twin donors), and 5 from unrelated or related non-sibling donors. 21 patients entered complete remission, while 15 had persistent disease following repopulation of the marrow. 14 patients were not evaluable for remission status because of early transplantation-related death. The overall median survival from bone marrow transplantation was 27 months, with a projected long-term survival of 34 {\%}. Patients who were 40 yr of age or older had a survival that was not different from that of patients between 29 and 40 yr of age. The median disease-free survival of patients who entered complete remissions was 41 months. These patients tended to have a longer survival than patients with persistent disease following repopulation of the marrow. Allogeneic bone marrow transplantation appears bo be a promising method for treatment of certain patients with multiple myeloma.",
author = "G. Gahrton and S. Tura and C. Belanger and M. Cavo and B. Chapvis and A. Ferrant and M. Flesch and M. Gore and A. Gratwohl and Graven, {P. J.} and Harrouseau, {J. L.} and A. Lindeberg and P. Ljungman and B. Lowenberg and G. Lucarelli and {Michall et}, M. and J. Reiffers and O. Ringden and {Van Lint}, {M. T.}",
year = "1989",
language = "English",
volume = "43",
pages = "182--185",
journal = "Scandinavian journal of haematology. Supplementum",
issn = "0902-4506",
publisher = "Wiley-Blackwell",
number = "51",

}

TY - JOUR

T1 - Allogeneic bone marrow transplantation in patients with multiple myeloma

AU - Gahrton, G.

AU - Tura, S.

AU - Belanger, C.

AU - Cavo, M.

AU - Chapvis, B.

AU - Ferrant, A.

AU - Flesch, M.

AU - Gore, M.

AU - Gratwohl, A.

AU - Graven, P. J.

AU - Harrouseau, J. L.

AU - Lindeberg, A.

AU - Ljungman, P.

AU - Lowenberg, B.

AU - Lucarelli, G.

AU - Michall et, M.

AU - Reiffers, J.

AU - Ringden, O.

AU - Van Lint, M. T.

PY - 1989

Y1 - 1989

N2 - 50 patients with a median age of 41 years (range 29-54) underwent allogeneic bone marrow transplantation for multiple myeloma. 35 patients were on second-line treatment, and 15 on first-line treatment. 24 patients were considered refractory to previous treament. 45 patients received marrow from HLA-matched sibling donors (3 of these from twin donors), and 5 from unrelated or related non-sibling donors. 21 patients entered complete remission, while 15 had persistent disease following repopulation of the marrow. 14 patients were not evaluable for remission status because of early transplantation-related death. The overall median survival from bone marrow transplantation was 27 months, with a projected long-term survival of 34 %. Patients who were 40 yr of age or older had a survival that was not different from that of patients between 29 and 40 yr of age. The median disease-free survival of patients who entered complete remissions was 41 months. These patients tended to have a longer survival than patients with persistent disease following repopulation of the marrow. Allogeneic bone marrow transplantation appears bo be a promising method for treatment of certain patients with multiple myeloma.

AB - 50 patients with a median age of 41 years (range 29-54) underwent allogeneic bone marrow transplantation for multiple myeloma. 35 patients were on second-line treatment, and 15 on first-line treatment. 24 patients were considered refractory to previous treament. 45 patients received marrow from HLA-matched sibling donors (3 of these from twin donors), and 5 from unrelated or related non-sibling donors. 21 patients entered complete remission, while 15 had persistent disease following repopulation of the marrow. 14 patients were not evaluable for remission status because of early transplantation-related death. The overall median survival from bone marrow transplantation was 27 months, with a projected long-term survival of 34 %. Patients who were 40 yr of age or older had a survival that was not different from that of patients between 29 and 40 yr of age. The median disease-free survival of patients who entered complete remissions was 41 months. These patients tended to have a longer survival than patients with persistent disease following repopulation of the marrow. Allogeneic bone marrow transplantation appears bo be a promising method for treatment of certain patients with multiple myeloma.

UR - http://www.scopus.com/inward/record.url?scp=0024832968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024832968&partnerID=8YFLogxK

M3 - Article

VL - 43

SP - 182

EP - 185

JO - Scandinavian journal of haematology. Supplementum

JF - Scandinavian journal of haematology. Supplementum

SN - 0902-4506

IS - 51

ER -